Cyanotech Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2020
KAILUA KONA, Hawaii--(BUSINESS WIRE)--Feb 11, 2020--
Cyanotech Corporation (Nasdaq Capital Market: CYAN), a world leader in microalgae-based, high-value nutrition and health products, announced financial results for the third quarter and first nine months of fiscal year 2020, ended December 31, 2019.
Third Quarter Fiscal 2020
Cyanotech reported net sales of $7,504,000 for the third quarter of fiscal 2020 compared to $10,044,000 for the third quarter of fiscal 2019. Gross profit was $2,877,000, with gross profit margin of 38.3%, compared to gross profit of $4,116,000 and gross profit margin of 41.0%. Operating income was $367,000 compared to $495,000. Net income was $171,000 or $0.03 per diluted share, compared to net income of $288,000 or $0.05 per diluted share.
Commenting on the third quarter fiscal 2020 results (changes shown vs. the third quarter of fiscal 2019), Cyanotech’s Chief Executive Officer, Gerald R. Cysewski, Ph.D., said:
“Though our sales for the third quarter are below last year’s unusual level, on a nine-month basis our sales volume and profit margins appear to be normalizing. With closer attention to costs and business infrastructure, the company has been generating cash and reducing payables. Absent contrary circumstances, we expect the company to be profitable this fiscal year.”
Providing further detail about the fiscal results, Cyanotech’s Chief Financial Officer, Brian B. Orlopp, added:
“Inclement and cool weather this past quarter impacted production which affected our gross margins. We believe our results are best viewed over a longer time frame than any one given quarter to take into account the seasonal variation of our production.”
Nine Months Fiscal 2020
For the first nine months of fiscal 2020 compared to the nine months ended December 31, 2018, net sales were $23,265,000 compared to $24,143,000. Gross profit was $9,615,000, with gross margin of 41.3%, compared to $8,237,000 and 34.1%, respectively. Net income was $266,000 or $0.04 per diluted share, compared to net loss of ($2,123,000) or ($0.37) per diluted share.
Please review the Company’s Form 10-Q for the period ended December 31, 2019 for more detailed information.
— Cyanotech will host a Skype broadcast at 8:00 PM EST on Wednesday, February 12, 2020 to respond to questions about its operating results and other topics of interest. Interested parties are asked to submit questions to email@example.com before 12 p.m. (noon) EST on Wednesday, February 12, 2020. The Company will respond only to relevant questions relating to the Company’s third quarter fiscal 2020 financial performance and will not be accepting any questions or comments during the broadcast.
To join the broadcast, please browse http://cyanotech.com/meet approximately five minutes prior to the start time.
About Cyanotech — Cyanotech Corporation, a world leader in microalgae technology for more than 30 years, produces BioAstin® Hawaiian Astaxanthin® and Hawaiian Spirulina Pacifica®. These all-natural, dietary ingredients and supplements leverage our experience and reputation for quality, building nutritional brands which promote health and well-being. The Company’s mission is to fulfill the promise of whole health through Hawaiian microalgae. Cyanotech’s BioAstin® offers superior antioxidant activity which supports skin, eye and joint health, as well as recovery from exercise*. Cyanotech’s Spirulina products offer nutrition that supports cardiovascular health and immunity.* All Cyanotech products are produced from microalgae grown at our 96-acre facility in Kona, Hawaii using patented and proprietary technology and are Generally Recognized as Safe (GRAS) for use in food products. Cyanotech sells its products direct to consumers at retail locations in the United States and online at www.nutrex-hawaii.com and also distributes to dietary supplement, nutraceutical and cosmeceutical manufacturers and marketers. The Company is regulated by the FDA. Visit www.cyanotech.com for more information.
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.
“Safe Harbor” Statement under the U.S. Private Securities Litigation Reform Act of 1995 Besides statements of present fact and historical fact, this press release may contain forward-looking statements. Forward-looking statements relate to the future and are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by forward-looking statements. We caution against relying on forward-looking statements. Important factors that could change actual, future results include: changes in sales levels to our largest customers, weather patterns in Hawaii, production problems, risks associated with new products, foreign exchange fluctuations, and availability of financing, as well as national and global political, economic, business, competitive, market and regulatory conditions. Other factors are more fully detailed in the Company’s annual Form 10-K filings with the Securities and Exchange Commission.
Financial Tables Follow: The following tables do not contain footnotes or other information contained in the Company’s Form 10-Q for the third quarter fiscal 2020 ended December 31, 2019, which can be found on the Cyanotech website ( www.cyanotech.com ) under Investors>Investor Filings upon filing. As such the following Financial Tables are provided only as a guide and other factors are more fully detailed in the Company’s annual Form 10-K filings with the Securities and Exchange Commission.
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except per share amounts)
Accounts receivable, net of allowance for doubtful accounts of $13 at December 31, 2019 and $27 at March 31, 2019
Prepaid expenses and other current assets
Total current assets
Equipment and leasehold improvements, net
Operating lease right-of-use assets, net
LIABILITIES AND STOCKHOLDERS’ EQUITY
Operating lease obligations, current portion
Short-term contract obligation
Line of credit
Current maturities of long-term debt
Total current liabilities
Long-term debt, less current maturities
Long-term operating lease obligations
Other long-term liabilities
Commitments and contingencies
Preferred stock of $0.01 par value, authorized 10,000,000 shares; no shares issued and outstanding
Common stock of $0.02 par value, authorized 50,000,000 shares; issued and outstanding 5,925,717 shares at December 31, 2019 and 5,879,710 shares at March 31, 2019
Additional paid-in capital
Total stockholders’ equity
Total liabilities and stockholders’ equity
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share amounts)
Three Months Ended
Nine Months Ended
Cost of sales
General and administrative
Sales and marketing
Research and development
Total operating expenses
Income (loss) from operations
Interest expense, net
Income (loss) before income taxes
Income tax expense
Net income (loss)
Net income (loss) per share:
Shares used in calculation of net income (loss) per share:
View source version on businesswire.com:https://www.businesswire.com/news/home/20200211005306/en/
CONTACT: Bruce Russell
KEYWORD: UNITED STATES NORTH AMERICA HAWAII
INDUSTRY KEYWORD: GENERAL HEALTH CONSUMER FITNESS & NUTRITION PUBLIC RELATIONS/INVESTOR RELATIONS SCIENCE WOMEN BIOTECHNOLOGY SENIORS COMMUNICATIONS ALTERNATIVE MEDICINE OTHER SCIENCE HEALTH
SOURCE: Cyanotech Corporation
Copyright Business Wire 2020.
PUB: 02/11/2020 08:00 AM/DISC: 02/11/2020 08:01 AM